CO2023007904A2 - Formulación de polvo seco de muteína de lipocalina para el tratamiento del asma - Google Patents
Formulación de polvo seco de muteína de lipocalina para el tratamiento del asmaInfo
- Publication number
- CO2023007904A2 CO2023007904A2 CONC2023/0007904A CO2023007904A CO2023007904A2 CO 2023007904 A2 CO2023007904 A2 CO 2023007904A2 CO 2023007904 A CO2023007904 A CO 2023007904A CO 2023007904 A2 CO2023007904 A2 CO 2023007904A2
- Authority
- CO
- Colombia
- Prior art keywords
- dry powder
- powder formulation
- asthma
- lipocalin mutein
- treatment
- Prior art date
Links
- 102000019298 Lipocalin Human genes 0.000 title abstract 3
- 108050006654 Lipocalin Proteins 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000843 powder Substances 0.000 title abstract 3
- 208000006673 asthma Diseases 0.000 title abstract 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 abstract 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención está relacionada con el tratamiento del asma en un sujeto humano mediante la administración por inhalación oral de una formulación de polvo seco que comprende una cantidad con eficacia terapéutica de una muteína de lipocalina contra el receptor alfa de IL-4 (IL-4Rα), o una variante o fragmento de esta, a dicho sujeto. La invención también está relacionada con la formulación de polvo seco que comprende la muteína de lipocalina contra el receptor alfa de IL-4 (IL-4Rα), o una variante o un fragmento de esta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127903P | 2020-12-18 | 2020-12-18 | |
| PCT/EP2021/086730 WO2022129629A1 (en) | 2020-12-18 | 2021-12-20 | Lipocalin mutein dry powder formulation for treatment of asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023007904A2 true CO2023007904A2 (es) | 2023-10-30 |
Family
ID=79686778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0007904A CO2023007904A2 (es) | 2020-12-18 | 2023-06-16 | Formulación de polvo seco de muteína de lipocalina para el tratamiento del asma |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4262845A1 (es) |
| JP (1) | JP2023553703A (es) |
| KR (1) | KR20230121785A (es) |
| CN (1) | CN116916945A (es) |
| AR (1) | AR124436A1 (es) |
| AU (1) | AU2021399151A1 (es) |
| CA (1) | CA3199479A1 (es) |
| CL (1) | CL2023001775A1 (es) |
| CO (1) | CO2023007904A2 (es) |
| CR (1) | CR20230265A (es) |
| IL (1) | IL303729A (es) |
| MX (1) | MX2023007174A (es) |
| PE (1) | PE20240799A1 (es) |
| TW (1) | TW202241490A (es) |
| WO (1) | WO2022129629A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| KR101516023B1 (ko) | 2006-08-01 | 2015-04-30 | 피어이스 에이지 | 눈물 리포칼린 돌연변이 단백질 및 이를 얻는 방법 |
| ES2729652T3 (es) | 2010-06-08 | 2019-11-05 | Pieris Pharmaceuticals Gmbh | Muteína de lipocalina lacrimal unidas a IL-4R alpha |
| SG10201604566QA (en) | 2011-12-13 | 2016-07-28 | Pieris Ag | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| WO2020201038A1 (en) * | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| KR20210146934A (ko) | 2019-03-29 | 2021-12-06 | 아스트라제네카 에이비이 | 천식 치료를 위한 리포칼린 뮤테인 |
-
2021
- 2021-12-20 JP JP2023536889A patent/JP2023553703A/ja active Pending
- 2021-12-20 AU AU2021399151A patent/AU2021399151A1/en active Pending
- 2021-12-20 CR CR20230265A patent/CR20230265A/es unknown
- 2021-12-20 EP EP21844230.9A patent/EP4262845A1/en active Pending
- 2021-12-20 IL IL303729A patent/IL303729A/en unknown
- 2021-12-20 CA CA3199479A patent/CA3199479A1/en active Pending
- 2021-12-20 AR ARP210103583A patent/AR124436A1/es unknown
- 2021-12-20 CN CN202180085274.3A patent/CN116916945A/zh active Pending
- 2021-12-20 TW TW110147707A patent/TW202241490A/zh unknown
- 2021-12-20 KR KR1020237023191A patent/KR20230121785A/ko unknown
- 2021-12-20 MX MX2023007174A patent/MX2023007174A/es unknown
- 2021-12-20 PE PE2023001901A patent/PE20240799A1/es unknown
- 2021-12-20 WO PCT/EP2021/086730 patent/WO2022129629A1/en active Application Filing
-
2023
- 2023-06-15 CL CL2023001775A patent/CL2023001775A1/es unknown
- 2023-06-16 CO CONC2023/0007904A patent/CO2023007904A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230265A (es) | 2023-09-29 |
| IL303729A (en) | 2023-08-01 |
| PE20240799A1 (es) | 2024-04-18 |
| AU2021399151A1 (en) | 2023-07-27 |
| CN116916945A (zh) | 2023-10-20 |
| KR20230121785A (ko) | 2023-08-21 |
| EP4262845A1 (en) | 2023-10-25 |
| AR124436A1 (es) | 2023-03-29 |
| CA3199479A1 (en) | 2022-06-23 |
| JP2023553703A (ja) | 2023-12-25 |
| CL2023001775A1 (es) | 2024-01-19 |
| TW202241490A (zh) | 2022-11-01 |
| MX2023007174A (es) | 2023-09-08 |
| WO2022129629A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21051833A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| CL2019003924A1 (es) | Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485). | |
| UY30901A (es) | Nuevos metodos | |
| AR077573A2 (es) | Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende | |
| SV2008002855A (es) | Milnacipran para el tratamiento a largo plazo del sindrome de fibromialgia | |
| CL2011003003A1 (es) | Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria. | |
| TR201908938T4 (tr) | Ağız, boğaz ve solunum yolu rahatsızlıklarının tedavisi için formülasyonlar. | |
| PA8784901A1 (es) | Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial | |
| PE20211489A1 (es) | Formas de dosificacion pediatricas de vitamina d, metodos de elaboracion y uso | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| CO2020013427A2 (es) | Formulaciones de ciclosporina para uso en el tratamiento del síndrome de bronquiolitis obliterante (bos) | |
| DOP2017000055A (es) | Tratamientos médicos a base de anamorelina | |
| AR072951A1 (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
| CO2023007904A2 (es) | Formulación de polvo seco de muteína de lipocalina para el tratamiento del asma | |
| CO2022008001A2 (es) | Métodos para el tratamiento de trastornos depresivos | |
| EA200801824A1 (ru) | Лечебно-профилактический состав для ухода за полостью рта | |
| UY31097A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante | |
| CO2023009085A2 (es) | Pauta posológica de levodopa | |
| BR112018010497A2 (pt) | combinação sinérgica de ácido pirrolidona-carboxílico e/ou seus sais e de ácido hialurônico e/ou seus sais para utilização no tratamento e/ou prevenção de secura e irritação da mucosa e suas formulações farmaceuticas relacionadas | |
| UY37907A (es) | 3-fenilquinazolin-4 (3h)-onas sustituidas y sus usos | |
| BR112023003536A2 (pt) | Composições para tratamento bucal que compreendem flavonoides prenilados | |
| BR112012007399A2 (pt) | composição de cuidado oral, usos da interleucina-1 recombinante humana e métodos para reduzir o mau hálito e para o tratamento ou prevenção de doença periodontal. | |
| EA202192662A1 (ru) | Мутеин липокалина для лечения астмы | |
| AR075783A1 (es) | Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales | |
| AR061046A1 (es) | Mirtazapina para el tratamiento del dolor neuropatico |